

Ioannis T Farmakis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2675511/ioannis-t-farmakis-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19 papers	40 citations	3 h-index	5 g-index
25 ext. papers	89 ext. citations	2.7 avg, IF	2.07 L-index

#	Paper	IF	Citations
19	Autonomic Neuromodulation for Atrial Fibrillation Following Cardiac Surgery: JACC Review Topic of the Week.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 682-694	15.1	0
18	Temporal trends in the efficacy of revascularization in stable ischaemic heart disease: A cumulative meta-analysis.. <i>American Journal of Preventive Cardiology</i> , 2022 , 10, 100340	1.9	
17	Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). <i>Hellenic Journal of Cardiology</i> , 2021 ,	2.1	1
16	Predictive Role of Platelet-Associated Indices on Admission and Discharge in the Long-Term Prognosis of Acute Coronary Syndrome Patients. <i>Angiology</i> , 2021 , 33197211052134	2.1	0
15	Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 77, 397-407	3.1	11
14	Comparative Analysis of Risk Stratification Scores in Atrial Fibrillation. <i>Current Pharmaceutical Design</i> , 2021 , 27, 1298-1310	3.3	1
13	Cardio-protective Effects of Glucagon-like Peptide-1 Receptor Agonists: An Overview of Systematic Reviews and Publication Overlap. <i>Current Pharmaceutical Design</i> , 2021 , 27, 1068-1079	3.3	2
12	Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial. <i>Atherosclerosis</i> , 2021 , 323, 37-43	3.1	3
11	Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 1137-1150	5.1	1
10	Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	3
9	The spectrum of COVID-19 in complex adult congenital heart disease: A case series.. <i>International Journal of Cardiology Congenital Heart Disease</i> , 2021 , 3, 100097	0.7	
8	Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
7	Atrial High-Rate Episodes in Patients with Devices Without a History of Atrial Fibrillation: a Systematic Review and Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	3
6	Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021 , 68, 102036	3.5	0
5	Comparative efficacy and safety of oral P2Y inhibitors for patients with chronic kidney disease and acute coronary syndrome: a network meta-analysis. <i>Hellenic Journal of Cardiology</i> , 2021 , 63, 40-40	2.1	0
4	Low-density lipoprotein cholesterol target value attainment based on 2019 ESC/EAS guidelines and lipid-lowering therapy titration for patients with acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 2314-2317	3.9	3
3	Risk for Recurrent Cardiovascular Events and Expected Risk Reduction With Optimal Treatment 1 Year After an Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2020 , 133, 7-14	3	2

2	Treatment practices and lipid profile of patients with acute coronary syndrome: results from a tertiary care hospital. <i>Acta Cardiologica</i> , 2020 , 75, 527-534	0.9	4
1	Motivational interviewing to support LDL-C therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes (IDEAL-LDL) study: rationale and design. <i>Hellenic Journal of Cardiology</i> , 2019 , 60, 249-253	2.1	5